Drive to end cancer could pioneer diagnostic technology
GRAIL, the developer of multi-cancer early detection test Galleri, is building on its earlier commercial partnership with the UK’s National Health Service. That partnership aims to confirm Galleri’s clinical and economic performance in the UK healthcare system, which is one step toward regular use by the NHS. GRAIL recently presented its first results for PATHFINDER, an interventional study evaluating Galleri, specifically studying people ages 50 and older because of their increased risk of cancer. None of the study participants had suspicion of active cancer when the...